* Regulus Therapeutics Inc reported a quarterly adjusted loss of 21 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -40 cents. The mean expectation of six analysts for the quarter was for a loss of 17 cents per share. Wall Street expected results to range from -19 cents to -13 cents per share.

* Reported revenue was zero​; analysts expected zero.

* Regulus Therapeutics Inc's reported EPS for the quarter was a loss of 21 cents​.

* The company reported a quarterly loss of $14.06 million.

* Regulus Therapeutics Inc shares had fallen by 3.8% this quarter and gained 18.0% so far this year.

FORECAST CHANGES

* The mean earnings estimate of analysts had risen by about 7.3% in the last three months.​

* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Regulus Therapeutics Inc is $7.50 This summary was machine generated from LSEG data November 8 at 02:19 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Sep. 30 2024 -0.17 -0.21 Missed

Jun. 30 2024 -0.15 -0.17 Missed

Mar. 31 2024 -0.22 -0.29 Missed

Dec. 31 2023 -0.39 -0.40 Missed